Get the Stockscreener App
44.48
4.28%
-1.99
After Hours:
44.52
0.04
+0.09%
Avidity Biosciences Inc stock is traded at $44.48, with a volume of 1.99M.
It is down -4.28% in the last 24 hours and up +31.75% over the past month.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
See More
Previous Close:
$46.47
Open:
$46.11
24h Volume:
1.99M
Relative Volume:
0.88
Market Cap:
$5.72B
Revenue:
$10.12M
Net Income/Loss:
$-280.49M
P/E Ratio:
-15.39
EPS:
-2.89
Net Cash Flow:
$-188.51M
1W Performance:
-2.84%
1M Performance:
+31.75%
6M Performance:
+39.00%
1Y Performance:
-1.11%
1-Day Range:
$44.37
$46.49
1-Week Range:
$44.37
$47.50
52-Week Range:
$21.51
$56.00
Avidity Biosciences Inc Stock (RNA) Company Profile
Name
Avidity Biosciences Inc
Sector
Industry
Phone
858-401-7900
Address
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare RNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
44.48 | 5.98B | 10.12M | -280.49M | -188.51M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.88 | 100.71B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.87 | 58.84B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.91 | 61.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
661.32 | 40.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
319.32 | 38.20B | 3.81B | -644.79M | -669.77M | -6.24 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Buy |
| Jun-24-25 | Initiated | Bernstein | Outperform |
| Jun-17-25 | Initiated | Wolfe Research | Outperform |
| Jun-11-25 | Initiated | Raymond James | Strong Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-20-24 | Initiated | H.C. Wainwright | Buy |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-24 | Initiated | Goldman | Buy |
| Aug-28-24 | Initiated | Barclays | Overweight |
| May-03-24 | Initiated | BofA Securities | Buy |
| Mar-14-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-22-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-31-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Strong Buy |
| Sep-07-21 | Initiated | Evercore ISI | Outperform |
| Jun-17-21 | Initiated | Needham | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | Cowen | Outperform |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | SVB Leerink | Outperform |
| Jul-07-20 | Initiated | Wells Fargo | Overweight |
View All
Avidity Biosciences Inc Stock (RNA) Latest News
Avidity Biosciences Inc. Charts Flash Early Recovery SignalsEarnings Overview Summary & Fast Gain Swing Trade Alerts - newsimpact.co.kr
Myotonic Dystrophy Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma, Lupin - Barchart.com
Technical analysis overview for Avidity Biosciences Inc. stockWeekly Trading Summary & Verified Momentum Watchlists - Newser
Momentum Indicator Shows Bearish Divergence in Avidity Biosciences Inc.July 2025 Technicals & Low Drawdown Momentum Trade Ideas - metal.it
Avidity Biosciences Q2 Earnings: Strong Progress and Financial Position - AInvest
Price Floor Holding on Avidity Biosciences Inc. — Rebound PossibleWeekly Stock Analysis & Weekly Sector Rotation Insights - metal.it
Novartis Reportedly Eyeing To Acquire Avidity Biosciences: But Retail Expects Management To Sell Only At Significant Premium - MSN
What makes Avidity Biosciences Inc. stock price move sharplyJuly 2025 Weekly Recap & Accurate Entry/Exit Alerts - thegnnews.com
Avidity Biosciences Advances RNA Therapeutics with Strong Q2 - TipRanks
Avidity Biosciences (RNA) CHRO McCarthy sells $465k in stock - Investing.com
Avidity Biosciences Executives Sell Shares Under Trading Plans - TradingView
Avidity Biosciences Executives Make Substantial Share Trades Amid Company News - AInvest
Avidity Biosciences’ SWOT analysis: RNA stock poised for growth in rare muscle disease market - Investing.com
Avidity Biosciences Inc. Moves Into Overbought Range Analysts CautiousTrend Analysis for Safer Trades Gains Popularity - 선데이타임즈
Avidity Biosciences RNA 2025Q2 Earnings Preview Upside Potential on Novartis Acquisition Talks - AInvest
Avidity Biosciences Maintains Strong Buy Rating With $75 Price Target - AInvest
Avidity Biosciences Bets Big On Rare Disease Therapies - Finimize
Avidity Biosciences Q2 Results: Analysts Boost Revenue Forecasts, Raise Loss Per Share Estimates - AInvest
The Avidity Biosciences, Inc. (NASDAQ:RNA) Second-Quarter Results Are Out And Analysts Have Published New Forecasts - Yahoo Finance
Avidity Biosciences Rockets As Novartis Reportedly Mulls A Takeover Deal - MSN
A Quick Look at Today's Ratings for Avidity Biosciences(RNA.US), With a Forecast Between $60 to $78 - 富途牛牛
Avidity (RNA) Gets 26% Jump on Potential Takeover - MSN
Avidity Biosciences price target raised to $75 from $70 at Wells Fargo - MSN
Chardan Capital Maintains "Buy" Rating for Avidity Biosciences with $75 Price Target - AInvest
Insider Selling at Avidity Biosciences: A Signal of Routine Tax Obligations or a Cause for Concern? - AInvest
Avidity Biosciences Insider Selling: Signal or Noise in a High-Potential Biotech Play? - AInvest
Avidity Biosciences Shares Slide 2.59% as 230M-Dollar Volume Ranks 431st Amid Analyst Optimism and Deepening Losses - AInvest
Avidity Biosciences Signs Manufacturing Agreement with Lonza - The Globe and Mail
Avidity Biosciences Insider Trading: Officers Buy and Sell Shares on 2025-08-06 - AInvest
Novartis weighs deal for biotech Avidity Biosciences, FT reports - AOL.com
Avidity Biosciences: Strong Buy Rating Backed by Promising Clinical Outcomes and Robust Financial Position - TipRanks
Avidity Biosciences: Wells Fargo maintains a 'Overweight' Rating, The Target Price is $75 - AInvest
Avidity Biosciences: Barclays Keeps Overweight Rating, Raises PT to $62 - AInvest
A Quick Look at Today's Ratings for Avidity Biosciences(RNA.US), With a Forecast Between $60 to $75 - 富途牛牛
Barclays Maintains Avidity Biosciences(RNA.US) With Buy Rating, Raises Target Price to $62 - 富途牛牛
Avidity Biosciences: Chardan Capital Maintains Buy, Raises PT to $75 - AInvest
Avidity Biosciences 2025 Q2 Earnings Significant Loss Widening Despite Revenue Surge - AInvest
Avidity (RNA) Q2 Revenue Jumps 88% - AOL.com
Avidity Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Avidity Biosciences Reports Q2 2025 Financial Results and Key Milestones, with Strong Cash Position and Upcoming FDA Submissions - AInvest
Avidity Biosciences: Promising Pipeline and Strategic Developments Drive Buy Rating Amid Potential Novartis Takeover Interest - AInvest
Avidity Biosciences reports Q2 EPS ($1.21), consensus (96c) - TipRanks
Earnings Flash (RNA) Avidity Biosciences, Inc. Reports Q2 Revenue $3.8M - MarketScreener
Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights - Nasdaq
Avidity Bio Climbs on Report of Novartis Takeover - MSN
Novartis eyes Avidity Biosciences in potential takeover: Report - Medical Dialogues
Rumour mill says Novartis may want to buy Avidity - pharmaphorum
Novartis's Strategic Pursuit of Avidity Biosciences: A Catalyst for Biotech Value and Long-Term Growth? - AInvest
Avidity Biosciences Surges 26% on 877% Volume Spike to 121st Most Traded as High-Volume Stocks Outperform with 166% Returns - AInvest
Novartis Eyes Avidity Biosciences Acquisition to Boost Rare Disease Pipeline - AInvest
Avidity Shares Surge 20% Following Report of Buyout Interest - AInvest
Avidity Biosciences Inc Stock (RNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):